Patent · US Active

Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

US12216120B2 · kind B2 · utility

0Cited by
53References
20Claims
0Family size

Assignee

Inventors

Key dates

Filing dateMar 18, 2022
Grant dateFeb 4, 2025
Priority date—
Expiry dateSep 23, 2042

Classification

  • Technology area (CPC G)Physics
  • CPC primaryG01N2469/10
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present disclosure is directed to antibodies binding to and neutralizing the coronavirus designated SARS-CoV-2 and methods for use thereof.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.